Stonegate Capital Partners Updates Coverage on Aemetis, Inc. (AMTX) Q4 2024

Rhea-AI Summary

Aemetis (NASDAQ: AMTX) reported significant growth in FY24, with revenues increasing 43% to $268.0 million from $187.0 million in FY23. The company posted a net loss of $87.5 million, primarily due to interest expenses.

Key operational highlights include doubled RNG capacity and a 55% growth in ethanol revenue, driven by sustainability investments. The India Biofuels segment showed strong performance with a 20% revenue increase and 50% production growth, alongside ongoing IPO plans.

The company ended Q4 2024 with $0.898 million in cash, expecting a higher cash position in Q1 2025 following the sale of $16.8 million in transferable investment tax credits in February 2025. Regulatory support through LCFS, E15, and 45Q/45Z credits are identified as potential growth catalysts.

Positive

• Revenue growth of 43% to $268.0M in FY24
• Doubled RNG capacity with 55% growth in ethanol revenue
• India Biofuels segment showed 20% revenue growth and 50% production increase
• Expected cash boost of $16.8M from tax credits sale in February 2025

Negative

• Net loss of $87.5M primarily from interest expenses
• Low cash position of $0.898M at year-end 2024

Dallas, Texas--(Newsfile Corp. - March 28, 2025) - Aemetis, Inc. (NASDAQ: AMTX): Stonegate Capital Partners updates coverage on Aemetis, Inc. (NASDAQ: AMTX), highlighting strong growth across its renewable energy segments. Full year revenues increased 43% to $268.0M, up from $187.0M in FY23. This resulted in a net loss of $87.5M, which was largely impacted by interest expenses. The Company ended the year with $0.898M in cash, with a higher cash balance expected at 1Q25 end following the sale of $16.8M in transferable investment tax credits in February of 2025.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Aemetis doubled RNG capacity and grew ethanol revenue by 55%, driven by sustainability investments.
• India Biofuels revenue rose 20%, with production up 50% and IPO plans underway.
• Regulatory support like LCFS, E15, and 45Q/45Z credits offer major tailwinds--pending political clarity.

Click image above to view full announcement.

---

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking, equity research and capital raising for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246463

FAQ

What was Aemetis (AMTX) revenue growth in FY 2024?

Aemetis reported a 43% revenue increase to $268.0 million in FY24, up from $187.0 million in FY23.

How much was Aemetis (AMTX) net loss in FY 2024?

Aemetis recorded a net loss of $87.5 million in FY24, mainly due to interest expenses.

What was the performance of AMTX India Biofuels segment in 2024?

The India Biofuels segment achieved 20% revenue growth with a 50% increase in production, with IPO plans in progress.

How much cash did Aemetis (AMTX) have at the end of Q4 2024?

Aemetis had $0.898 million in cash at the end of Q4 2024, with expectations of higher cash balance in Q1 2025 after $16.8M tax credits sale.

What regulatory support factors could benefit AMTX growth?

LCFS, E15, and 45Q/45Z credits are identified as major regulatory tailwinds for Aemetis, pending political clarity.